---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-019199"
form_type: "8-K"
ticker: "AURX"
cik: "0001091596"
company_name: "Nuo Therapeutics, Inc."
filed_at: "2026-06-02T21:41:56+00:00"
generated_at: "2026-06-03T10:08:35.148362+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nuo Therapeutics secures $2M loan facility; issues warrants at $1.50 strike

## Summary
- Amended loan agreement increases aggregate commitment by $400k to $2.0M; $675k funded on May 29, 2026.
- Interest rate raised to 12% on all outstanding notes; interest payable via warrants, not cash.
- Warrants issued at $1.50 exercise price, expiring Jan 23, 2031; includes diverse warrant types.
- Lenders include director Scott Pittman (>10% owner) and Paul Jacobs (>5% owner); proceeds for working capital.
- Mandatory prepayment triggers upon equity financing ≥$5M, change of control, or default.

## SEC filing metadata
- accession: 0001437749-26-019199
- form_type: 8-K
- ticker: AURX
- cik: 0001091596
- company_name: Nuo Therapeutics, Inc.
- filed_at: 2026-06-02T21:41:56+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1091596/000143774926019199/0001437749-26-019199-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1091596/000143774926019199/aurx20260602_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-019199
- JSON: https://secwatch.observer/filing/0001437749-26-019199.json
- Plain text: https://secwatch.observer/filing/0001437749-26-019199.txt

## Key facts
- Debt Financings
  Nuo Therapeutics, Inc. incurred credit facility of aggregate principal amount of up to $2.0 million with $1,000,000 previously funded on January 23, 2026, $675,000 funded with Scott M. Pittman and four other lenders at annual rate of 12% (increased from 10% on prior notes) maturing December 31, 2028.
  - Instrument: credit facility
  - Principal: aggregate principal amount of up to $2.0 million with $1,000,000 previously funded on January 23, 2026, $675,000 funded
  - Counterparty: Scott M. Pittman and four other lenders
  - Rate: annual rate of 12% (increased from 10% on prior notes)
  - Maturity: December 31, 2028
  - Event: incurrence
  source text: On May 29, 2026, Nuo Therapeutics, Inc. (the “Company”) entered into an Amended and Restated Loan and Security Agreement (the “Interim Loan Agreement”) with five lenders (collectively, the “Lenders”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1091596/000143774926019199/0001437749-26-019199-index.htm
- Equity Issuances
  Nuo Therapeutics, Inc. issued shares of the Company's common stock of warrant to five lenders (collectively, the 'Lenders') for issued as loan fees and for accrued interest.
  - Security: warrant
  - Shares: shares of the Company's common stock
  - Purchaser: five lenders (collectively, the 'Lenders')
  - Consideration: issued as loan fees and for accrued interest
  source text: On May 29, 2026, the closing date of the Interim Funding, and pursuant to the Interim Loan Agreement, the Company (a) issued to each Lender warrants, a portion of which are subject to vesting provisions, to purchase shares of the Company’s common stock, (b) cancelled certain warrants previously issued pursuant to the Initial Funding, and (c) again agreed to issue additional warrants to each Lender in the Interim Funding to purchase shares of the Company’s common stock as payment for accrued interest under the Notes.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1091596/000143774926019199/0001437749-26-019199-index.htm
- Material Agreements
  Nuo Therapeutics, Inc. amended Amended and Restated Loan and Security Agreement with five lenders valued at $2.0 million (effective 2026-05-29).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: five lenders
  - Value: $2.0 million
  - Effective: 2026-05-29
  source text: On May 29, 2026, Nuo Therapeutics, Inc. (the “Company”) entered into an Amended and Restated Loan and Security Agreement (the “Interim Loan Agreement”) with five lenders (collectively, the “Lenders”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1091596/000143774926019199/0001437749-26-019199-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.